Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ANNX
ANNX logo

ANNX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Annexon Inc (ANNX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.960
1 Day change
-0.80%
52 Week Range
7.180
Analysis Updated At
2026/03/26
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Annexon Inc (ANNX) is not a compelling buy at this moment for a beginner investor with a long-term focus. The stock lacks strong positive catalysts, has weak technical indicators, and no significant trading signals. While the financial performance shows improvement in net income and EPS, the company remains unprofitable, and there is no recent news or influential trading activity to support a strong buy recommendation.

Technical Analysis

The technical indicators for ANNX suggest a neutral to slightly bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 45.406, and moving averages are converging, indicating no clear trend. The stock is trading below its pivot level of 5.43, with key support at 5.052 and resistance at 5.808.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • The stock has a 70% chance to gain 3.38% in the next week and 8.8% in the next month based on historical candlestick patterns. Financial metrics such as net income and EPS have shown significant YoY improvement.

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts. The stock has declined 2.14% in the regular market session and an additional 0.38% post-market. Hedge funds and insiders are neutral, with no significant trading trends. The company remains unprofitable with zero revenue growth.

Financial Performance

In Q3 2025, Annexon reported a net income of -$54.92M, which is an improvement of 57.71% YoY. EPS improved by 48% YoY to -0.37. However, revenue and gross margin remain at zero, indicating no operational revenue generation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available for ANNX.

Wall Street analysts forecast ANNX stock price to rise
6 Analyst Rating
Wall Street analysts forecast ANNX stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.000
sliders
Low
8
Averages
16.4
High
27
Current: 5.000
sliders
Low
8
Averages
16.4
High
27
Chardan
Daniil Gataulin
Buy
initiated
$16
AI Analysis
2025-12-23
Reason
Chardan
Daniil Gataulin
Price Target
$16
AI Analysis
2025-12-23
initiated
Buy
Reason
Chardan analyst Daniil Gataulin initiated coverage of Annexon with a Buy rating and $16 price target. The firm cites the commercial potential of the company's complement C1q inhibitors tanruprubart in Guillain-Barre syndrome and vonaprument in geographic atrophy for the Buy rating. It sees additional upside potential from tanruprubart in Huntington's disease.
Wells Fargo
NULL
to
Overweight
upgrade
$14 -> $27
2025-11-19
Reason
Wells Fargo
Price Target
$14 -> $27
2025-11-19
upgrade
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Annexon to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument's Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ANNX
Unlock Now

People Also Watch